{"product_id":"getinge-swot-analysis","title":"Getinge SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUse SWOT Analysis to Assess Getinge's Investment Profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGetinge's SWOT highlights its global footprint and broad medical technology portfolio alongside regulatory, pricing, and execution risks; the full analysis examines competitive positioning, R\u0026amp;D priorities, and scenario-based implications to support informed investment review. Purchase the complete SWOT to access a research-backed, editable Word and Excel package-suited for investor presentations, strategy reviews, and due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Share in Sterile Reprocessing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge remains a global leader in infection control and sterile reprocessing, supplying critical infrastructure to over 70,000 hospitals; its installed base drives high entry barriers and recurring service and consumables revenue-sterile reprocessing accounted for roughly 28% of group sales, about SEK 13.5bn in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Acute Care Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge offers an integrated acute care portfolio-ventilators, ECMO (extracorporeal membrane oxygenation) and OR solutions-that served hospitals in 90+ countries and drove medical systems sales contributing 42% of Getinge's 2024 net sales (SEK 36.4bn).\u003c\/p\u003e\n\u003cp\u003eThis breadth lets major health systems consolidate vendors, cutting procurement steps and lowering service complexity; bundled contracts reduced support incidents by up to 18% in client case studies.\u003c\/p\u003e\n\u003cp\u003eEnd-to-end OR offerings strengthen Getinge as a strategic partner for large health systems, supporting recurring consumables and service revenue that improved segment margins in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Global Service and Support Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith operations in over 40 countries, Getinge runs a large service organization that boosts equipment uptime-Getinge reported service revenue of SEK 9.8 billion in 2024, up 6% year-on-year.\u003c\/p\u003e\n\u003cp\u003eThis global network is a competitive edge as hospitals shift to long-term maintenance contracts and demand rapid technical response; service agreements now represent ~34% of group revenues.\u003c\/p\u003e\n\u003cp\u003eDeep customer relationships from field service drive loyalty and lower churn, while service-derived feedback shortens product R\u0026amp;D cycles and supported 12 product updates in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion in the Life Science Sector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGetinge has diversified into life sciences, growing bioprocessing and lab equipment sales to 22% of group revenue by Q4 2025, up from 9% in 2020, tapping rising biopharma production demand.\u003c\/p\u003e\n\u003cp\u003eThe division leverages Getinge's specialized engineering and service capabilities, delivering higher gross margins (approx. 28% in 2025 vs 18% for hospital hardware) and stronger recurring service revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% group revenue from life science (Q4 2025)\u003c\/li\u003e\n\u003cli\u003e28% gross margin in life science (2025)\u003c\/li\u003e\n\u003cli\u003eHigher recurring service mix\u003c\/li\u003e\n\u003cli\u003eBiopharma production growth supporting demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Commitment to R and D Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGetinge reinvests around 6.0% of 2024 net sales (≈SEK 2.1bn) into R and D, keeping pace with medical tech peers and funding digital health and automation developments.\u003c\/p\u003e\n\u003cp\u003eRecent launches-AI-enabled workflow software and automated sterilization lines-cut process errors by up to 30% in pilot hospitals and speed cycles, improving clinical outcomes tied to reduced infection rates.\u003c\/p\u003e\n\u003cp\u003eEngineering tied to outcome metrics (e.g., shorter OR turnover, lower SSI rates) keeps Getinge relevant as hospitals shift to data-driven procurement and value-based care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR and D spend ~6.0% of revenue (2024, ≈SEK 2.1bn)\u003c\/li\u003e\n\u003cli\u003ePilots show up to 30% error reduction\u003c\/li\u003e\n\u003cli\u003eFocus on outcomes: lower SSI and faster OR turnover\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGetinge: Sterile Reprocessing \u0026amp; Acute Care Drive Growth - 34% Services, 22% LifeSci\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGetinge leads sterile reprocessing (≈SEK 13.5bn, 28% of 2025 sales) and acute care (42% of 2024 sales, SEK 36.4bn), with service revenue SEK 9.8bn (34% of group) and life sciences at 22% of revenue (Q4 2025); R\u0026amp;D ~6.0% of 2024 sales (≈SEK 2.1bn), life-science gross margin ~28% (2025), pilots cut errors up to 30%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSterile reprocessing\u003c\/td\u003e\n\u003ctd\u003eSEK 13.5bn (28%, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute care\u003c\/td\u003e\n\u003ctd\u003e42% net sales (SEK 36.4bn, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService revenue\u003c\/td\u003e\n\u003ctd\u003eSEK 9.8bn (34%, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLife sciences\u003c\/td\u003e\n\u003ctd\u003e22% (Q4 2025); GM 28% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e≈6.0% (≈SEK 2.1bn, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of Getinge, outlining its internal strengths and weaknesses alongside external opportunities and threats to assess strategic positioning and future growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for Getinge that streamlines strategic alignment and accelerates executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Quality and Regulatory Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge has a documented history of quality-control lapses and regulatory scrutiny-culminating in a 2018 FDA consent decree and multiple recalls that led to over SEK 1.2 billion (≈USD 110m) in remediation costs through 2023.\u003c\/p\u003e\n\u003cp\u003eThese enforcement actions triggered fines, warranty charges, and legal reserves that dented operating margins; Getinge reported a 2024 adjusted operating margin roughly 2-3 percentage points below peers partly due to compliance spend.\u003c\/p\u003e\n\u003cp\u003eBrand trust in key markets weakened, slowing elective purchasing cycles and contributing to a 2024 organic revenue decline of about 4%; remediation and sustained compliance efforts remain material cost drivers in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Hospital Capital Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa large portion of getinge revenue depends on hospital capital budgets making sales cyclical in roughly orders came from equipment segments exposing it to budget cuts. when inflation and rising labor costs squeeze margins hospitals defer big-ticket purchases surgical sterilization increasing quarterly volatility. this dependence complicates multi-year forecasting raises sensitivity macro swings.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Profit Margins in Surgical Workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe Surgical Workflows segment at Getinge reported lower operating margins than Acute Care and Life Science, with 2024 segment EBIT margin around mid-single digits versus group EBIT margin of 9.3% in 2024; intense competition and commoditization of disposables and basic instruments have eroded pricing power, cutting ASPs (average selling prices) in some markets by ~5-8% since 2021. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity in Global Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGetinge's global manufacturing footprint raises supply risk: a 2023 supplier interruption delayed shipments, contributing to a 4.1% revenue shortfall in Q4 2023 vs plan and pushing COGS up 180 basis points in FY2023.\u003c\/p\u003e\n\u003cp\u003eLogistics bottlenecks and raw-material shortages-semiconductor and specialty-steel constraints in 2022-24-have caused multi-week lead-time spikes and higher freight costs, squeezing margins.\u003c\/p\u003e\n\u003cp\u003eManaging dozens of specialized suppliers across 20+ countries remains a constant operational strain that can limit ability to meet peak hospital demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023: supplier outage → 4.1% revenue miss\u003c\/li\u003e\n\u003cli\u003eFY2023: COGS +180 bps\u003c\/li\u003e\n\u003cli\u003e20+ countries, multi-week lead-time spikes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Integration Risk from Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGetinge has grown via acquisitions-19 deals from 2018-2024 including the 2022 Stericlin acquisition-but integrating diverse cultures and IT\/quality systems raises cultural and operational hurdles.\u003c\/p\u003e\n\u003cp\u003eFailed integrations risk losing key talent; Getinge reported restructuring costs of SEK 1.2bn in 2023 and management time diverted from organic R\u0026amp;D and sales growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e19 acquisitions (2018-2024)\u003c\/li\u003e\n\u003cli\u003eSEK 1.2bn restructuring costs in 2023\u003c\/li\u003e\n\u003cli\u003eTalent attrition and system harmonization risk\u003c\/li\u003e\n\u003cli\u003eManagement bandwidth diverted from organic growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGetinge under pressure: SEK2.4bn hits, -4% organic, 9.3% EBIT, 45% capital risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGetinge faces persistent quality\/regulatory costs (SEK 1.2bn restructuring + ≈SEK 1.2bn remediation through 2023), weaker brand trust that cut organic revenue ~4% in 2024, high capital-sales cyclicality (~45% orders from capital equipment in 2024), margin pressure (group EBIT 9.3% in 2024; Surgical Workflows mid-single digits), supply-chain shocks (2023 supplier outage → 4.1% revenue miss; FY2023 COGS +180bps).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRemediation \u0026amp; restructuring\u003c\/td\u003e\n\u003ctd\u003e≈SEK 2.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic revenue change (2024)\u003c\/td\u003e\n\u003ctd\u003e-4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital orders (2024)\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup EBIT (2024)\u003c\/td\u003e\n\u003ctd\u003e9.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS change (FY2023)\u003c\/td\u003e\n\u003ctd\u003e+180bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2023 revenue miss (quarter)\u003c\/td\u003e\n\u003ctd\u003e4.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eGetinge SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eYou're viewing a live preview of the actual SWOT analysis file. The complete version becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Digital Health and AI Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe integration of AI and digital connectivity into ORs and ICUs gives Getinge a major growth runway, as global hospital AI market size hit about $12.1B in 2024 and CAGR ~28% (2024-29). Getinge can turn its installed hardware base into SaaS-workflow and decision tools-that command higher gross margins (software often 60-80%) versus devices. By 2025 demand for data-driven tools is strong: 70% of hospitals plan AI investments within 24 months, opening new recurring revenue streams and faster service-led growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Healthcare Access in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAsia-Pacific and Latin America are upgrading hospitals: WHO reports 30%+ surgical volume growth in South Asia (2019-2023), and Latin America health spending rose 4.6% CAGR (2015-2022), creating demand for Getinge's surgical and sterilization systems.\u003c\/p\u003e\n\u003cp\u003eCapturing 1-2% of these markets could add €150-€300m in annual revenue by 2028, assuming regional device markets grow to €15-€20bn; local sales teams and service hubs cut delivery times and improve margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Demand for Biopharmaceutical Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGetinge can capture rising demand as global biologics sales reached $340B in 2024 (IQVIA) and are forecast to grow ~8% CAGR to 2030; its Life Science division supplies bioprocessing and sterile transfer gear crucial for personalized medicine manufacturing.\u003c\/p\u003e\n\u003cp\u003eBioprocessing equipment markets grew ~10% in 2023-24 with gross margins ~20-30%, higher than traditional medtech; Getinge's focused product mix could lift divisional margins and revenue resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Sustainability and Green Medtech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRising demand for low-energy, low-water healthcare gear lets Getinge push sustainable sterilizers and climate-neutral plants to win contracts-hospital procurement tied to ESG grew 28% globally in 2024 per McKinsey.\u003c\/p\u003e\n\u003cp\u003eGreen leadership could lift brand value and attract investors: 2024 ESG-focused AUM hit $35.5 trillion, and Getinge reporting lower Scope 1-3 emissions would match buyer needs.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eDevelop low-energy sterilizers\u003c\/li\u003e\n\u003cli\u003eDecarbonize manufacturing by 2030\u003c\/li\u003e\n\u003cli\u003eTarget ESG-linked tenders (28% growth)\u003c\/li\u003e\n\u003cli\u003eSignal reduced Scope 1-3 emissions\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships in Personalized Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborating with pharma and research institutes on personalized medicine lets Getinge access niche, high-margin markets; the global cell and gene therapy market hit $5.9B in 2024 and is forecast to reach ~$24B by 2030, so equipment providers can capture rapid upside.\u003c\/p\u003e\n\u003cp\u003eBy supplying sterilization, bioreactors, and closed-system processing for cell and gene therapy production, Getinge can embed itself in next-gen care pathways and recurring consumables revenue.\u003c\/p\u003e\n\u003cp\u003ePartnerships give early access to technologies and influence future clinical standards, reducing time-to-adoption and supporting long-term service contracts and aftermarket sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCell \u0026amp; gene therapy market: $5.9B (2024)\u003c\/li\u003e\n\u003cli\u003eForecast CAGR ~25% to 2030 (~$24B)\u003c\/li\u003e\n\u003cli\u003eRevenue model: equipment + consumables + services\u003c\/li\u003e\n\u003cli\u003eStrategic value: early tech access, clinical standard-setting\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGetinge: AI, biologics \u0026amp; ESG could unlock €150-300m by 2028\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAI-enabled OR\/ICU SaaS, bioprocessing for biologics\/cell \u0026amp; gene, and ESG-linked tenders offer Getinge recurring-revenue growth; capture of 1-2% regional device markets could add €150-€300m by 2028, biologics market €340B (2024) at ~8% CAGR to 2030, cell \u0026amp; gene $5.9B (2024) to ~$24B (~25% CAGR), and 28% growth in ESG-tied procurement (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eKey 2024\/2025 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI in hospitals\u003c\/td\u003e\n\u003ctd\u003e$12.1B market (2024), CAGR ~28% (24-29)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics\u003c\/td\u003e\n\u003ctd\u003e$340B (2024), ~8% CAGR to 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell \u0026amp; gene\u003c\/td\u003e\n\u003ctd\u003e$5.9B (2024) → ~$24B (2030), ~25% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eESG tenders\u003c\/td\u003e\n\u003ctd\u003e28% procurement growth (2024); ESG AUM $35.5T (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue upside\u003c\/td\u003e\n\u003ctd\u003e€150-€300m potential (1-2% share by 2028)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense Competition from Global Medtech Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGetinge faces fierce competition from global medtech giants like Baxter International, Medtronic, and Dräger, each with comparable global reach and larger 2024 R\u0026amp;D spends (Medtronic $3.8B, Baxter $680M, Dräger ~€200M), pressuring margins.\u003c\/p\u003e\n\u003cp\u003eThese rivals can deploy aggressive pricing and scale: Medtronic reported 2024 revenue $31.5B, Baxter $12.6B, enabling market share moves in critical care and surgical consumables.\u003c\/p\u003e\n\u003cp\u003eTo defend position, Getinge must sustain rapid product innovation and a lean cost base; its 2024 operating margin (~7-8%) leaves limited room versus peers with higher scale efficiencies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent and Evolving Regulatory Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe medical technology sector faces rising global regulatory stringency that can delay product launches and raise R\u0026amp;D costs; Getinge reported regulatory-related CAPEX and compliance spending of SEK 2.1 billion in 2024, up 18% year-on-year. Changes like the EU Medical Device Regulation (MDR) require ongoing investment in technical documentation and clinical evidence, extending approval timelines by 6-12 months on average. Failure to comply risks market exclusion, recall costs, and fines-under MDR penalties can reach several million euros-and may harm revenue from key markets such as the EU and U.S.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic Volatility and Inflationary Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpglobal economic instability-with global cpi still elevated at in and central banks hiking rates through getinge cost of capital borrowing squeezing free cash flow.\u003e\n\u003cprising energy yoy in europe labor growth key markets and raw-material costs compress margins if price increases can be fully passed to hospitals clinics.\u003e\n\u003cpcurrency swings hurt reported earnings: sek weakness versus usd in trimmed revenue translation for sweden-headquartered firms like getinge amplifying volatility.\u003e\n\u003c\/pcurrency\u003e\u003c\/prising\u003e\u003c\/pglobal\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Technological Obsolescence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rapid pace of medical tech means Getinge's devices risk obsolescence without regular R\u0026amp;D updates; global medtech venture funding hit $27.7B in 2024, fueling startups with disruptive sterilization and OR tech that can undercut legacy systems.\u003c\/p\u003e\n\u003cp\u003eCompetitors' digital platforms and AI-enabled sterilization monitoring can cut costs 10-25%, pressuring Getinge's margins; Getinge spent ~SEK 4.1B on R\u0026amp;D in 2024, so agility is critical to match clinical shifts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh startup funding: $27.7B (2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend: SEK 4.1B (2024)\u003c\/li\u003e\n\u003cli\u003eCost-cutting potential of new tech: 10-25%\u003c\/li\u003e\n\u003cli\u003eRisk: faster clinical practice shifts = market share loss\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Tensions and Trade Barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cprising geopolitical tensions can trigger tariffs export controls and local-content rules that disrupt getinge global operations raise costs in medical trade barriers rose year increasing procurement complexity. conflicts or sanctions key markets delay shipments reduce sales of revenue came from apac a region with elevated risk. these risks lie mostly outside company control but sharply stress supply chains.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: global medical trade barriers +12%\u003c\/li\u003e\n\u003cli\u003e2023: APAC share of revenue 18%\u003c\/li\u003e\n\u003cli\u003eTariffs and export controls increase lead times\u003c\/li\u003e\n\u003cli\u003eLocalized manufacturing may raise capex and OPEX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/prising\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGetinge under pressure: rivals, rising regulatory costs and inflation squeeze margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGetinge faces margin pressure from larger rivals (Medtronic rev $31.5B 2024; Baxter $12.6B 2024) and rising compliance costs (SEK 2.1B regulatory spend 2024). Inflation, energy (+20% Europe 2023-24) and wage rises (~4-6%) squeeze cash flow; currency swings (SEK vs USD\/EUR) add volatility. Faster-startup innovation ($27.7B VC 2024) and stricter MDR delays (avg +6-12 months) risk market share loss.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023-24\/2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedtech VC funding\u003c\/td\u003e\n\u003ctd\u003e$27.7B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGetinge R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eSEK 4.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003eSEK 2.1B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy rise Europe\u003c\/td\u003e\n\u003ctd\u003e+20% (2023-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53668028875094,"sku":"getinge-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/getinge-swot-analysis.webp?v=1778885045","url":"https:\/\/balancedscorecardexamples.com\/products\/getinge-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}